Melita Medical

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis4 trials
• Crohn's disease3 trials
• Obesity2 trials
• Hidradenitis suppurativa1 trial

Phase

• Phase 34 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting2 trials

Lead sponsor

• Eli Lilly and Company4 trials
• Bluefin Biomedicine, Inc.1 trial
• OSE Immunotherapeutics1 trial
• Shire1 trial

Running trials

• Active, not recruiting

  A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

  NCT07287644· Phase 2/3· Bluefin Biomedicine, Inc.· Source

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Jaroslaw Leszczyszyn (principal investigator)

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: Jaroslaw Leszczyszyn (principal investigator)

• Active, not recruiting

  A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Crohn's disease1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis

  NCT04882007· Phase 2· OSE Immunotherapeutics· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Shire· Source